Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,567 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Regimen Clear all
Completed Phase 3 Interventional Results available

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

NCT03363854
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 30, 2026, 3:32 PM EDT
Completed Phase 4 Interventional

An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients

NCT00352261
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Esomeprazole, Lansoprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
12
States / cities
Phoenix, Arizona • Tucson, Arizona • North Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2009 · Synced Oct 30, 2026, 3:32 PM EDT
Completed Not applicable Interventional Results available

User-Led Meaningful Activity and Early-Stage Dementia

NCT05159869
View directory record Official record
Conditions
Dementia
Interventions
User-Led Meaningful Activity Plan
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 30, 2026, 3:32 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine

NCT02629861
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
178
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 30, 2026, 3:32 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Scheduled or as Needed Pain Regimen?

NCT06495632
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Motrin and narcotic
Drug
Lead sponsor
Cape Fear Valley Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Fayetteville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 30, 2026, 3:32 PM EDT
Completed Phase 3 Interventional Results available

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

NCT02311907
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome, Pain, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions
Carboplatin, Glutathione, Laboratory Biomarker Analysis, Paclitaxel, Placebo, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
390
States / cities
Mobile, Alabama • Fairbanks, Alaska • Scottsdale, Arizona + 259 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 30, 2026, 3:32 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)

NCT07221565
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation
Interventions
Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN)
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 30, 2026, 3:32 PM EDT
Completed Not applicable Interventional Results available

Individualized Exercise Oncology Program for Newly Diagnosed Breast Cancer Patients

NCT04106609
View directory record Official record
Conditions
Breast Cancer
Interventions
Supervised, individualized exercise oncology program, Current standard of care
Other
Lead sponsor
Karen Wonders
Other
Eligibility
30 Years to 80 Years · Female only
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 30, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

NCT03467932
View directory record Official record
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
Cohort A: ORMD-0801, Placebo oral capsule, Cohort B: ORMD-0801
Drug
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 30, 2026, 3:32 PM EDT
Terminated Phase 4 Interventional

Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1

NCT00781287
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
3-drug anti-HIV therapy, Raltegravir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Oct 30, 2026, 3:32 PM EDT
Active, not recruiting Phase 4 Interventional

Liraglutide Effect in Atrial Fibrillation

NCT03856632
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Liraglutide, RFM, Anti Arrhythmics, Afib Catheter Ablation
Drug · Other · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 30, 2026, 3:32 PM EDT
Completed Phase 3 Interventional Results available

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

NCT03895203
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab, Adalimumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Phoenix, Arizona • San Diego, California • Tustin, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 30, 2026, 3:32 PM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis

NCT01431820
View directory record Official record
Conditions
Distal and Lateral Subungual Onychomycosis
Interventions
Luliconazole Solution, 10%, Vehicle Solution
Drug
Lead sponsor
Topica Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
28
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2015 · Synced Oct 30, 2026, 3:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study is to Evaluate a Regimen on Gingivitis Using Traditional and Novel Assessment Methods

NCT07211061
View directory record Official record
Conditions
Gingivitis
Interventions
Stannous Fluoride Dentifrice, Sodium Fluoride Dentifrice, electric toothbrush, Cetylpyridinium Chloride (CPC), manual toothbrush
Drug · Device
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 30, 2026, 3:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects

NCT05918588
View directory record Official record
Conditions
Immune System Disorder (Healthy Volunteer)
Interventions
Belumosudil mesylate, Placebo
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 30, 2026, 3:32 PM EDT
Completed Phase 3 Interventional Results available

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

NCT00975286
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Lixisenatide (AVE0010), Placebo, Insulin glargine, Pen auto-injector, Metformin, Thiazolidinedione (TZD)
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
23
States / cities
Mesa, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Oct 30, 2026, 3:32 PM EDT
Completed Phase 3 Interventional Results available

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

NCT02294227
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Secukinumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
19
States / cities
Mesa, Arizona • Upland, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 30, 2026, 3:32 PM EDT
Completed Not applicable Interventional Results available

A Safety and Effectiveness Study of a New Contact Lens Cleaning and Disinfecting Solution

NCT02701556
View directory record Official record
Conditions
Contact Lens Wear
Interventions
Complete MPS, NNR06
Device
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Pittsburg, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 30, 2026, 3:32 PM EDT
Terminated Phase 3 Interventional Results available

The Everolimus-Transplant Exit Strategy Trial (E-TEST)

NCT01636466
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Everolimus
Drug
Lead sponsor
Ashtar Chami
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 30, 2026, 3:32 PM EDT
Terminated Not applicable Interventional Results available

Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis

NCT02296346
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
SoluMedrol, Extracorporeal Photopheresis
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 30, 2026, 3:32 PM EDT
Completed Phase 1 Interventional

Effects of Delta9-tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R33 Study

NCT04080427
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Placebo capsule, Dronabinol 7.5 milligram oral capsule
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 60 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 30, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas

NCT04917861
View directory record Official record
Conditions
Zika Virus
Interventions
mRNA-1893, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
808 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
3
States / cities
Sioux City, Iowa • Lenexa, Kansas • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 30, 2026, 3:32 PM EDT
Withdrawn Not applicable Interventional

Dynamic Splinting for Plantarflexion in Spastic Hemiplegia

NCT01329705
View directory record Official record
Conditions
Spastic Hemiplegia
Interventions
Ankle Dorsiflexion Dynasplint, Standard of care
Device · Other
Lead sponsor
Dynasplint Systems, Inc.
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Oct 30, 2026, 3:32 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

SARS Coronavirus Vaccine (SARS-CoV)

NCT00533741
View directory record Official record
Conditions
Coronavirus (SARS-CoV)
Interventions
Aluminum hydroxide, Placebo, SARS-CoV
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 30, 2026, 3:32 PM EDT